| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 139, 7-15, Copyright © 1991 by American Society for Investigative Pathology
REGULAR ARTICLES |
B Ryffel, M Brockhaus, U Durmuller and F Gudat
Department of Pathology, University of Basel, Switzerland.
Tumor necrosis factor alpha (TNF alpha), which is produced by germinal center dendritic reticulum cells (DRC) in lymphoid tissue, plays a regulatory role in a local immune response. However no information is available on the nature and location of cells responding to this cytokine. Thus TNF receptor distribution was investigated in situ by immunohistochemistry using monoclonal antibodies directed against the p75 and p55 receptor proteins. Receptor expression was unique and restricted to the lymphoreticular tissue. The p75 receptor was found on activated lymphocytes and interdigitating reticulum cells of the T-cell area, whereas the p55 receptor was confined to the germinal center DRCs, which are the main site of TNF alpha production. The two receptor proteins were expressed on distinct cell populations of the lymphoid system and no coexpression was observed. Preliminary results indicate that TNF receptor (TNFR) expression is regulated; Upregulation of TNFR proteins was found in reactive hyperplasia together with increased TNF alpha expression. In lymphoproliferative disorders, expression of the p75 receptor and TNF alpha was found mainly in high-grade malignant non- Hodgkin lymphomas. In summary, TNF alpha produced by germinal center DRCs might regulate an in vivo immune response through autocrine and paracrine pathways. Thus TNF alpha might signal, through the distinct TNFR proteins, the p55 and p75 receptor, which are expressed on different cell types in lymphoid tissue.
This article has been cited by other articles:
![]() |
B. F. Skinnider and T. W. Mak The role of cytokines in classical Hodgkin lymphoma Blood, May 29, 2002; 99(12): 4283 - 4297. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Pfeifer, E. Levi, T. Petrogiannis-Haliotis, L. Lehmann, Z. Wang, and M. E. Kadin A Murine Xenograft Model for Human CD30+ Anaplastic Large Cell Lymphoma : Successful Growth Inhibition with an Anti-CD30 Antibody (HeFi-1) Am. J. Pathol., October 1, 1999; 155(4): 1353 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Jones, C. D.M. Fletcher, K. Pulford, A. Shahsafaei, and D. M. Dorfman The T-Cell Activation Markers CD30 and OX40/CD134 Are Expressed in Nonoverlapping Subsets of Peripheral T-Cell Lymphoma Blood, May 15, 1999; 93(10): 3487 - 3493. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Corcione, L. Ottonello, G. Tortolina, P. Tasso, F. Ghiotto, I. Airoldi, G. Taborelli, F. Malavasi, F. Dallegri, and V. Pistoia Recombinant Tumor Necrosis Factor Enhances the Locomotion of Memory and Naive B Lymphocytes From Human Tonsils Through the Selective Engagement of the Type II Receptor Blood, December 1, 1997; 90(11): 4493 - 4501. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. MAYRHOFER; Peyer's patch organogenesis---cytokines rule, OK? Gut, November 1, 1997; 41(5): 707 - 709. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Dressler, S Mathias, and R. Kolesnick Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system Science, March 27, 1992; 255(5052): 1715 - 1718. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |